Role of a type of amino acid in confusion related to liver diseases
Phase 2
- Conditions
- Health Condition 1: K709- Alcoholic liver disease, unspecified
- Registration Number
- CTRI/2019/08/020552
- Lead Sponsor
- Pavan kumar KV
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1)patient with hepatic encephalopathy diagnosed according to West Haven criteria.
2)All types of hepatic encephalopathy induced by autoimmune, viral, alcoholic, biliary etiology
Exclusion Criteria
1] presence of a major neuropsychiatric illness,
2] hypersensitivity to RIFAXIMINand BCAA,
3]Presence of inflammatory bowel diseases and intestinal obstruction
4]Serum creatinine levels > twice normal
5]Pregnant and lactating mothers
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1] To determine the effect of BCAA plus RIFAXIMIN in the resolution of hepatic encephalopathy compared with RIFAXIMIN aloneTimepoint: 7 days
- Secondary Outcome Measures
Name Time Method 1] To determine the effect of RIFAXIMIN plus BCAAon Serum ammonia levels. <br/ ><br>2]To determine the effect of RIFAXIMINplus BCAA on duration of hospital stay <br/ ><br>Timepoint: 7 days